We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov Menu

Application of Transcranial Direct Current Stimulation (tDCS) in Patients With Chronic Pain After Spinal Cord Injury

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01112774
Recruitment Status : Terminated (Funding ended)
First Posted : April 28, 2010
Last Update Posted : March 21, 2017
Information provided by (Responsible Party):
Felipe Fregni, Spaulding Rehabilitation Hospital

Brief Summary:

The purpose of this study is to determine whether the novel treatment of transcranial direct current stimulation (tDCS) could decrease the pain perception of those with spinal cord injury.

We will also determine whether these changes are correlated with the clinical outcome (pain reduction).

Condition or disease Intervention/treatment
Spinal Cord Injury Device: Transcranial direct current stimulation

Detailed Description:

The active tDCS stimulation sessions will be compared to sham stimulation.

More study details will be provided by Spaulding Rehabilitation Hospital.

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 24 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Participant, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: Investigation of the Mechanisms of Transcranial Direct Current Stimulation of Motor Cortex for the Treatment of Chronic Pain in Spinal Cord Injury
Study Start Date : April 2010
Primary Completion Date : August 14, 2013
Study Completion Date : August 14, 2013

Resource links provided by the National Library of Medicine

U.S. FDA Resources

Arm Intervention/treatment
Experimental: tDCS/Spinal cord injury
Subjects will be randomized to receive 10 sessions of either active or sham tDCS. Stimulation will be given on consecutive days (Monday- Friday) at 2 mA over the primary motor cortex area.
Device: Transcranial direct current stimulation
Stimulation will be applied at 2 mA for a total of 20 minutes.
Other Name: electrical stimulation, tDCS
Experimental: tDCS/Healthy subjects
Subjects will receive 2 sessions of stimulation: one active and one sham tDCS on two separate visits. The order in which they receive the stimulation will be randomized. Stimulation parameters will be at 2 mA for a total of 20 minutes.
Device: Transcranial direct current stimulation
Stimulation will be applied at 2 mA for a total of 20 minutes.
Other Name: electrical stimulation, tDCS

Primary Outcome Measures :
  1. Neurophysiological activity changes after treatment with tDCS [ Time Frame: baseline, 2 weeks treatment and follow up (2 weeks) ]
    Magnetic resonance spectroscopy (MRS), electroencephalogram (EEG), transcranial magnetic stimulation (TMS)

Secondary Outcome Measures :
  1. Pain changes [ Time Frame: Baseline, 2 weeks treatment and follow up (2 weeks) ]
    (i) Demographic Data; (ii) Visual analog scale (VAS) for pain; (iii) Analgesic use; (iv) Quality of Life Scale (QOLS); (v) Patient Global Assessment (PGA); (vi) Clinical Global Impression (CGI); (vii) Beck Depression Inventory (BDI); (viii) Visual Analog Scale (VAS) for anxiety; (ix) tDCS Side Effects Questionnaire; (x) Mini-mental status exam; and (xi) Validation of Blinding

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   18 Years to 64 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes

STUDY ELIGIBILITY CRITERIA (similar to the criteria of the Interstitial Cystitis Network)

  1. Providing informed consent to participate in the study
  2. 18 to 64 years old
  3. with traumatic spinal cord injury (complete or incomplete) - for instance, due to fall, car accident or gun shot; (for spinal cord injury only)
  4. stable chronic pain for at least the three preceding months(for spinal cord injury only)
  5. score higher or equal to 4cm (0 cm= 'no pain' and 10cm='worst possible pain') on the Visual Analogue Scale (VAS) for pain perception at the baseline/start of the treatment(for spinal cord injury only)
  6. refractoriness to drugs for pain relieve - such as tricyclic antidepressants, antiepileptic drugs and/or narcotics (pain resistant to at least 2 of these drugs supplied in adequate dosages for six months) (for spinal cord injury only)
  7. pain is not attributable to other causes, such as peripheral inflammation.
  8. No clinically significant or unstable medical or psychiatric disorder
  9. No history of substance abuse
  10. No neuropsychiatric comorbidity
  11. No implanted devices for pain control, such as vagal or deep brain stimulators
  12. No contraindications to tDCS:

    • metal in the head
    • implanted brain medical devices
  13. No pregnancy
  14. Eligible to MRI according to MRI screening checklist.
  15. No use of ventilators

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01112774

United States, Massachusetts
Spaulding Rehabilitation Hospital
Boston, Massachusetts, United States, 02115
Sponsors and Collaborators
Spaulding Rehabilitation Hospital
Principal Investigator: Felipe Fregni, PhD Spaulding Rehabilitation Hospital

Responsible Party: Felipe Fregni, Principal Investigator, Spaulding Rehabilitation Hospital
ClinicalTrials.gov Identifier: NCT01112774     History of Changes
Other Study ID Numbers: 2010p000190
First Posted: April 28, 2010    Key Record Dates
Last Update Posted: March 21, 2017
Last Verified: March 2017

Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No

Keywords provided by Felipe Fregni, Spaulding Rehabilitation Hospital:
Transcranial direct current stimulation
Spinal cord injury
Chronic pain
Brain excitability

Additional relevant MeSH terms:
Wounds and Injuries
Spinal Cord Injuries
Chronic Pain
Spinal Cord Diseases
Central Nervous System Diseases
Nervous System Diseases
Trauma, Nervous System
Neurologic Manifestations
Signs and Symptoms